We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Boston Scientific and Guidant Announce Merger

By HospiMedica staff writers
Posted on 27 Jan 2006
Following a dizzying round of bids from two companies since early December, Guidant Corp. More...
(Indianapolis, IN, USA) has announced that its board has approved and entered into a merger agreement with Boston Scientific (Natick, MA, USA), which will acquire Guidant for cash and stock worth U.S.$80 per share, or about $27 billion.

Only days earlier, Guidant announced a deal with Johnson & Johnson (J&J, New Brunswick, NJ, USA; www.jnj.com), which offered Guidant $71 per share, or about $24.2 billion. However, Boston Scientific has continued to increase its own offer for Guidant, which reached $73 per share in mid-January. After Boston Scientific heard about the Guidant/J&J deal, the company increased its offer to $80 per share.

Guidant and Boston Scientific believe their combined company should be attractive to shareholders. It will have leading positions in growth markets, notably cardiovascular devices, and have total revenues in 2006 of nearly $9 billion. "Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships, and an ability to pioneer lifesaving therapies for patients around the world,” observed Pete Nicholas, chairman of Boston Scientific.

When J&J began its courtship of Guidant, the company hoped to gain a foothold in the heart-defibrillator business, which is growing about 20% per year. J&J's initial offer of $24.5 billion was made in December 2004, but following malfunction problems at Guidant, it reduced its offer to $21.5 billion. Then Boston Scientific came into the game.

Boston Scientific has also entered into an agreement with Abbott Laboratories (Abbott Park, IL, USA), under which Boston will divest the vascular intervention and endovascular businesses of Guidant, while agreeing to share rights to Guidant's drug-eluting stent program. Boston will receive $4.1 billion from Abbott for the Guidant assets, a loan of $900 million, and Abbott's agreement to acquire $1.4 billion of Boston's common stock. This move is designed to help secure antitrust approvals for the Boston/Guidant transaction.






Related Links:
Boston Scientific
J&J
Guidant

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Medical Adhesive
MED 5570U
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.